CKDXF

Healthcare Biotechnology

Ceryvyn Therapeutics Limited

$0.01

+0.00 +0.00% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 1:53 PM ET	0.01

Key Stats

Market Cap

13.68M

Avg Volume

P/E (TTM)

0.06

EPS

$0.17

52W High

$0.44

52W Low

$0.01

Div. Yield

0.0%

Valuation

P/B Ratio

0.66

P/S Ratio

13679.78

EV/EBITDA

1.37

EV/Revenue

-16341.22

Margins

Gross Margin 100.0%

Operating Margin (1194700.0%)

Net Margin 33044500.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Assets

(12.6%)

Liquidity & Leverage

Current Ratio

13.78

Quick Ratio

13.43

Total Cash

30.02M

Total Debt

About

Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.

ceryvyn.com